Share Twitter LinkedIn Facebook Email Rita Sanghvi Mehta, MD, UC Irvine Health, talks about Cyclin-Dependent Kinases to Endocrine Therapy | Adding CDK-46 inhibitors to Frontline or 2nd-Line Setting at MOASC 2018.
2025 Breast Cancer Updates: Dr. Evanthia Roussos Torres on Biomarkers, Immunotherapy, and the Future of Treatment – MOASC Breast 6 Mins Read
FDA Approves Datopotamab Deruxtecan / Datroway from Eli Lilly in Treatment for Unresectable or Metastatic HR-Positive, HER2-Negative Breast Cancer Breast 2 Mins Read